TeamDrive
RUS

RUSNANO

http://en.rusnano.com/

RUSNANO was founded as a joint stock company in March 2011, through reorganization of state corporation Russian Corporation of Nanotechnologies. RUSNANO is instrumental in realizing government policies for nanoindustry growth, investing in financially effective high-technology projects that guarantee the development of new manufacturing within the Russian Federation. The company invests in nanotechnology companies directly and through investment funds. Its primary investment focus is in electronics, optoelectronics and telecommunications, healthcare and biotechnology, metallurgy and metalwork, energy, mechanical engineering and instrument making, construction and industrial materials, chemicals and petrochemicals. The Government of the Russian Federation owns 100 percent of the shares in RUSNANO. By the moment thanks to RUSNANO’s investments 73 plants and R&D centers are launched in 32 regions of Russia.

Management of the investment assets of RUSNANO are carried out by a limited liability company established in December 2013, RUSNANO Asset Management. Anatoly Chubais is Chairman of its Executive Board.

Media Center

  • 24 May 2018

    State Duma adopted a bill to simplify registration of drugs

    It will be possible to register drugs that have the same international nonproprietary names, but different trade names, and being manufactured at the same site. The corresponding government bill No. 327290-7 on amendments to the Federal Law “On Circulation of Medicines” was adopted by the State Duma in the third reading.

  • 23 May 2018

    Today’s realities in the development of local and contract manufacturing

    The representatives of pharmaceutical companies met at the forum of the Adam Smith Institute where they shared their views on the development of local and contract manufacturing. Victor Dmitriev, General Director of the Association of Russian Pharmaceutical Manufacturers, said that Russian manufacturers continue to consider the quality of their products as the most important issue.

  • 23 May 2018

    Russian Ministry included the Kirov region biotech cluster in its register

    The Ministry of Industry and Trade of Russia confirmed that the industrial biotechnology cluster of the Kirov region and its specialized organization “The Association of Industrial Biotechnology Cluster” comply with the requirements approved by the Decree of the Russian Government No. 779, dated July 31, 2016.

  • 22 May 2018

    Russian pharmaceutical market: stability in unstable environment

    According to DSM Group, in 2017, the Russian market was worth 1629 billion rubles, which 8% higher than in 2016. For the first time in three years, the market grew in dollar- and euro-denominated terms. In physical terms, the market growth is similar to the dynamics in value terms. Therefore, the factor of higher prices played virtually no role in expanding the market volume. In 2017, the main driver was the increase in the actual consumption of medicinal products, i.e., the growth in terms of sold packages.

Read more